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Abstract 
Background: Aspirin (ASA) is the most widely used medicine to prevent cardiovascular diseases; however, the 
mechanisms by which ASA exerts its anti-proliferative effect remain not fully understood. This study was designed to 
investigate whether miR-145 is involved in the regulation of vascular smooth muscle cells’ (VSMCs) proliferation and 
to determine the anti-inflammatory effects of ASA via its regulation of CD40 to provide a new theoretical basis for the 
pharmacological effect of aspirin.
Methods: The TNF-α induced proliferation model of VSMCs was divided into different groups with or without aspirin. 
Cell proliferation was detected by EdU; Real-time PCR was used to detect the mRNA expression of miR-145, CD40, and 
Calponin, a VSMCs differentiation marker gene. Western blot was used to detect the protein expression of CD40; ELISA 
was used to determine the concentrations of the inflammatory cytokine IL-6 in cell supernatants.
Results: The proliferation of VSMCs was stimulated by TNF-α and accompanied by decreased levels of Calponin. 
TNF-α also decreased the levels of miR-145 and increased the levels of CD40 and IL-6. Pretreatment with 20 μg/mL of 
aspirin in VSMCs could partially block the above-mentioned effects induced by TNF-α. The protective effects of ASA 
in VSMCs were reversed by a pretreatment with a miR-145 inhibitor. We also found that the expression of miR-145 in 
peripheral blood mononuclear cells in ischemic stroke patients was significantly increased after a 10-day treatment 
with aspirin.
Conclusion: miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhib-
iting the expression of CD40.
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Background
Atherosclerosis (AS) is the pathological basis of coronary 
heart disease and ischemic stroke (IS), which is charac-
terized by abnormal proliferation of vascular smooth 
muscle cells (VSMCs) [1, 2]. The abnormal elevation of 
growth regulating factors, cell factors and vasoactive 
substances under pathological conditions can activate 
the VSMCs’ proliferation signal or inhibit their anti-pro-
liferation signal, which in turn alter the gene expression 
profiles of VSMCs. In this case, the function and struc-
ture of VSMCs will be impaired and may cause them to 
migrate from the elastic plate into the endometrium and 
begin to proliferate. Excessive proliferation of VSMCs 
causes them to secrete a redundant extracellular matrix, 
which in turn causes the muscle tone in the cytoplasm 
of VSMCs to decrease and the number of organelles to 
increase, destroying the balance between proliferation 
and apoptosis.
miRNAs are short non-coding RNAs involved in the 
regulation of gene expression at the post-transcriptional 
level. miRNAs have been involved in the pathogenesis 
of a number of cardiovascular diseases. miR-145 is the 




*Correspondence:  grfw2012@aliyun.com 
†Xin Guo, Lijin Yu and Min Chen contributed equally to this work 
1 Department of Pharmacy, The Third Xiangya Hospital, Central South 
University, Changsha 410013, Hunan, China
Full list of author information is available at the end of the article
Page 2 of 10Guo et al. J Transl Med  (2016) 14:211 
localized to VSMCs [3]. In dedifferentiated VSMCs, miR-
145 is down-regulated and involved in the proliferation 
of VSMCs. In addition, miR-145 is a critical modulator 
of the VSMCs phenotype and proliferation [4, 5]. Over-
expression of miR-143/145 promotes VSMCs differen-
tiation and inhibits proliferation of VSMCs [6]. Boettger 
reported that the miR-143/145 gene cluster can regulate 
the contractile phenotype of VSMCs in miR-143/145-de-
ficient mice [7]. miRNAs partially bind to complemen-
tary target sites in mRNA at the 3′UTR to regulate gene 
expression. Jakob and his colleagues have reported that 
miR-145 regulates VSMCs phenotype by targeting Krüp-
pel-like factor 5 (KLF5) and helps control vascular neoin-
timal lesion formation [3]. Other target genes, including 
Rho-associated, coiled-coil containing protein kinase 
1 (ROCK1) and tripartite motif containing 2 (TRIM2), 
have also been identified as being controlled by miR-145 
in cancer [8, 9].
CD40 belongs to the tumor necrosis factor receptor 
superfamily and is mainly expressed on the surface of B 
cells [10]. CD40 plays a critical role in T cell-dependent 
immune responses by interacting with the CD40 ligand 
(CD40L) [11]. The interaction between CD40 and CD40L 
can activate T and B lymphocytes and induce, for example, 
the expression of cytokines IL-1, IL-2, IL-6 and TNF-α [10]. 
In peripheral blood cells, CD40 and CD40L levels are sig-
nificantly higher in patients with AS compared to normal 
controls [12]. CD40 and CD40L are also highly expressed in 
human atherosclerotic plaque, and the inhibition of CD40 
signaling improves plaque stability [13]. These observations 
suggest that the expression of CD40 and CD40L may con-
tribute to the formation of atherosclerosis.
Aspirin (ASA) is the most widely used medicine to 
prevent cardiovascular diseases and can inhibit CD40-
CD40L ligation and reduce inflammation, alleviate ath-
erosclerosis and stabilize plaque [14]. Plasma levels 
of sCD40L and TXA2 are elevated in atherosclerotic 
patients [15]. After administration of ASA to athero-
sclerotic patients, the release of sCD40L is significantly 
reduced via the suppression of the TXA2 generation [16]. 
As Riondino has reported, after being activated by some 
exogenous stimulus, sCD40L levels can be decreased by 
aspirin treatment both in vitro and in vivo [17]. As shown 
by previous reports, the interaction of CD40-CD40L 
induces VSMCs’ proliferation, whereas miR-145 and 
aspirin inhibits their proliferation [3, 18, 19]; however, 
whether the anti-proliferation effect of aspirin on VSMCs 
is mediated by a miR-145/CD40 dependent pathway 
remains unclear. In this study, we investigated the corre-
lation between miR-145 and the anti-proliferative effect 
of aspirin to evaluate whether miR-145 is involved in the 
anti-proliferation and anti-inflammation effects of aspi-
rin in VSMCs by inhibiting the expression of CD40.
Methods
Reagents
DMSO and TNF-α were purchased from Sigma (St. 
Louis, MO, USA). The miR-145 inhibitor and miR-145 
inhibitor control were purchased from RiboBio Co., LTD 
(Guangzhou, China). Aspirin was obtained from the 
National Institutes for Food and Drug Control.
Cell culture
Human aortic vascular smooth muscle cells were pur-
chased from Jennio Biotech Co., Ltd (Guangzhou, China) 
and were cultured in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10  % fetal bovine serum 
(Hyclone, American), 100 U/ml streptomycin and 100 U/
ml penicillin at 37 °C in a humidified atmosphere of 5 % 
CO2. VSMCs (3 ×  105) were transfected with a total of 
200 nM of the miR-145 inhibitor or the miR-145 inhibi-
tor control by using the Sofast transfection reagent (Xia-
men, China) according to the manufacturer’s instruction. 
Total RNA and protein were extracted from VSMCs after 
transfection for 24  h, and RT-PCR was performed to 
measure Calponin or CD40 mRNA and miR-145 expres-
sion, while the expression of CD40 protein was evalu-
ated by Western blot. The cell experimental groups were 
shown as follows: (1) DMSO: VSMCs were treated with 
a solvent as a blank control; (2) TNF-α: VSMCs were 
treated with TNF-α for 24  h; (3) +miR-145 inhibitor 
control: VSMCs were treated with TNF-α for 24 h after 
transfection with the miR-145 inhibitor control for 24 h; 
(4) +ASA: VSMCs were pretreated with aspirin for 1  h 
and then co-treated with TNF-α for 24 h; and (5) +miR-
145 inhibitor +ASA: VSMCs were pretreated with aspi-
rin for 1 h after transfection with the miR-145 inhibitor 
for 24 h. Then, VSMCs were treated with TNF-α for 24 h.
Measurement of IL‑6 levels
The concentrations of IL-6 in culture supernatants were 
measured by an ELISA Kit (Boster, China) according to 
the manufacturer’s instructions.
Cell proliferation assay
Cell growth assays were performed with the EdU Kit 
(RiboBio, China) according to the manufacturer’s 
instructions. The proliferation of VSMCs showed red flu-
orescence under a microscope, and the ratio of EdU posi-
tive cell numbers was recorded to represent the VSMCs 
proliferation level.
Real‑time PCR
Total RNA was isolated with a Trizol reagent (TaKaRa, 
Japan) according to the manufacturer’s protocol. cDNA 
was prepared using the PrimeScript 1st Strand cDNA 
Synthesis Kit (TaKaRa, Japan). SYBR Green RT-PCR 
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was performed using the following primers: Calponin: 
sense, 5′-AACCATACACAGGTGCAGTC-3′, anti-
sense, 5′-GATGTTCCGCCCTTCTCTTAG-3′; CD40: 
sense, 5′- GCAGGCACAAACAAG ACTGA-3′, anti-
sense, 5′-TCGTCGGGAAATTGATCTC-3′; GAPDH: 
sense, 5′-CTGCACCACCAACTGCTTAG-3′, anti-
sense, 5′-AGGTCCACCACTGACACGT T-3′. For RT-
PCR, amplification and detection were performed using 
the Real-time PCR Master Mix (ToYoBo, Japan) with 
the 7300 Real-Time PCR system (Applied Biosystems) 
according to the manufacturer’s protocol. The relative 
quantities were determined using the comparative CT 
method and were normalized to GAPDH for Calponin 
and CD40 mRNA and to U6 for miR-145 expression. All 
amplification reactions were performed in triplicate.
Western blot analysis
The total protein concentration was determined using the 
BCA Protein Assay Kit (RiboBio, China). Proteins were 
denatured by boiling for 5 min, separated on SDS-PAGE 
gels, and transferred to a PVDF membrane. After block-
ing with 0.5 % milk for 1 h, the membrane was incubated 
overnight with mouse anti-CD40 (Santa Cruz, 1:1000), 
mouse anti-GAPDH (Biyuntian, 1:1000), followed by 
washing and incubating with goat anti-mouse (Biyun-
tian, 1:5000). Proteins were visualized by BeyoECL Plus 
Western blotting detection kit (Biyuntian, China), and 
pictures were captured using ChemiDoc XRS+ Image 
system (Bio-Rad, USA).
Flow cytometry analysis
Cells were harvested, washed twice and resuspended 
with phosphate-buffered saline (PBS). A total of 100  μL 
VSMC suspension was added in each tube and stained 
with 5  μL of anti-CD40 antibody fluorescein isothiocy-
anate (FITC) for 30  min on ice in the dark. Then, cells 
were washed twice with PBS and were resuspended by 
100  μL PBS. Flow cytometry analysis was performed 
within 2  h using BD FACSC antoII flow cytometer (BD 
Biosciences, USA) and data were analyzed using FlowJo 
software (Tree Star, USA).
Subjects
Our study recruited 46 IS patients, all of which were 
enrolled at the Third Xiangya Hospital in Hunan, China 
from March 2015 to September 2015. All patients were 
Han Chinese, who lived in Changsha, China. IS was 
defined by focal neurological signs and was confirmed 
by brain CT and/or MRI using baseline conditions and 
brain CT using contrast medium after 48–72  h. The 
demographic characteristics of IS patients are shown in 
Table  1. The total RNA in the peripheral blood mono-
nuclear cells (PBMCs) was extracted from all enrolled 
patients before and after the 10-day treatment with aspi-
rin to determine the changes in miR-145 expression.
This study was approved by the Ethics Committee of 
the Third Xiangya Hospital of Central South Univer-
sity (No. 2015-S099), and written informed consent was 
obtained from all subjects.
Isolation of atherosclerotic plaque
The atherosclerotic plaques were obtained from AS 
patients using human carotid endarterectomy (CEA).
Statistical analyses
Data are presented as the mean ± SD and were compared 
using a one-way ANOVA, followed by the Student–New-
man–Keuls test. The difference of miR-145 expression 
before and after treatment with aspirin in IS patients was 
analyzed by using a paired t test. All analyses were con-
ducted using the SPSS 13.0 software, and a value of P < 
0.05 was considered to be statistically significant.
Results
miR‑145 expression after transfection with miR‑145 
inhibitor in VSMCs
The expression of miR-145 in VSMCs was determined 
by Real-time PCR after transfection with either miR-145 
(50, 100, 200 nmol/L) or the miR-145 inhibitor control for 
24 h. As shown in Fig. 1, the miR-145 inhibitor with 100 
and 200 nmol/L concentrations inhibited the expression 
of miR-145. However, the inhibiting effect of the miR-145 
inhibitor with the 200  nmol/L concentration was more 
significant. Then, VSMCs were transfected with miR-145 
at a 200 nmol/L concentration in following part.
miR‑145 mediates the anti‑proliferative effect of aspirin 
on VSMCs induced by TNF‑α
Abnormal proliferation of VSMCs plays a role in patholog-
ical processes of vascular diseases, such as atherosclerosis, 
Table 1 General characteristics of the IS patients
Parameter IS (n = 46)
Gender (male/female) 28/18
Age, year 56.23 ± 7.15
BMI, kg/m2 22.42 ± 2.81
SBP, mmHg 142 ± 15
DBP, mmHg 86 ± 8
Creatinine (Cr), μmol/L 85.56 ± 9.38
HDL-C, mmol/L 1.36 ± 0.32
LDL-C, mmol/L 2.53 ± 0.43
Triglyceride (TG), mmol/L 1.92 ± 0.49
Total cholesterol (TC), mmol/L 4.91 ± 0.82
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restenosis and hypertension [20–22]. In our research study, 
VSMCs proliferation and the anti-proliferative effects 
of aspirin in VSMCs were evaluated by EdU assays. As 
shown in Fig. 2a and b, VSMCs proliferation was induced 
in the TNF-α group. In the +ASA group, VSMCs prolif-
eration induced by TNF-α was inhibited by aspirin. The 
miR-145 inhibitor counteracts the anti-proliferative effect 
of aspirin on TNF-α treated VSMCs. The mRNA expres-
sion of Calponin, a VSMC differentiation marker gene, 
was determined by real-time PCR. The Calponin mRNA 
level decreased when VSMCs were treated with TNF-
α. Aspirin partly restored Calponin mRNA expression 
level. After transfection with the miR-145 inhibitor, the 
up-regulation of Calponin mRNA levels induced by aspi-
rin was overturned (Fig. 2c). Similarly, the flow cytometry 
data of CD40 protein expression in VSMCs indicate that 
proliferating VSMCs cells induced by TNF-α were having 
higher expression of CD40 and upon treatment with ASA 
it reversed (Fig. 3a, b, c). These data suggest that the inhi-
bition of miR-145 can reverse the effect of aspirin of up-
regulating Calponin mRNA expression in TNF-α treated 
VSMCs and that miR-145 mediates the anti-proliferative 
effect of aspirin in TNF-α treated VSMCs.
miR‑145 mediates the effect of aspirin on CD40 expression 
induced by TNF‑α
The levels of miR-145 and CD40 mRNA expression in 
VSMCs were determined by real-time PCR. Treatment 
of VSMCs with TNF-α significantly decreased the 
mRNA expression of miR-145 and increased the mRNA 
expression of CD40; whereas aspirin partially restored 
the mRNA level of miR-145 accompanied by a decrease 
in the mRNA level of CD40 compared to the TNF-α 
group. However, the effect of aspirin on miR-145 and 
CD40 mRNA expression was abolished in the +miR-145 
inhibitor +ASA group compared to the +ASA group 
(Fig. 4a, b). When compared with the TNF-α group, the 
miR-145 inhibitor control did not show any significant 
effect on miR-145 and CD40 mRNA expression after 
TNF-α administration. The expression of CD40 protein 
was determined by Western blot. As shown in Fig.  5, 
CD40 protein expression is consistent with CD40 mRNA 
expression in every group. In addition, we explored 
the effect of aspirin alone in the absence of TNF-α on 
VSMCs and found that aspirin treatment significantly 
increased the miR-145 expression and decreased the 
CD40 expression both at the mRNA and protein level 
(Fig. 6a, b, c).
miR‑145 mediates the effect of aspirin on IL‑6 induced 
by TNF‑α
The pro-inflammatory cytokine IL-6 plays an important 
role in cell proliferation and is involved in the processes 
of many cardiovascular diseases. The concentrations of 
IL-6 in cultured cell supernatants were measured with 
an ELISA Kit. The IL-6 concentration was found to be 
higher in the TNF-α group than in the DMSO group. 
Treatment of VSMCs with aspirin partially decreased the 
IL-6 concentration induced by TNF-α. When compared 
with +ASA group, the effect of aspirin on IL-6 level 
was abolished by the miR-145 inhibitor in the +miR-
145 inhibitor +ASA group (Fig. 7). Compared to TNF-α 
group, the miR-145 inhibitor control did not show any 
significant effect on IL-6 level induced by TNF-α.
The influence of aspirin on the expression of miR‑145 in IS 
patients
Aspirin is a commonly used drug for the treatment of 
IS. In this study, we used the stem loop primers of miR-
145 synthesized by Guangzhou RiboBio Co. to amplify 
miR-145 in the PBMCs from IS patients. Our data 
revealed that the expressions of miR-145 were signifi-
cantly elevated after the 10-day treatment of aspirin in 
IS patients, which suggested the increased expression of 
miR-145 in the IS patients may be partially induced by 
aspirin therapy (Fig. 8). Also, in this study, we collected 
several atherosclerotic plaque specimens from AS 
patients with or without aspirin treatment and found 
that the plaque from the patients treated with aspirin 
showed increased miR-145 levels and decreased CD40 
levels (Fig. 9a, b, c).
Fig. 1 miR-145 expression after transfection with miR-145 inhibitor 
in VSMCs. The level of miR-145 expression in VSMCs was evaluated by 
Real-time PCR after transfection with different concentrations of the 
miR-145 inhibitor for 24 h. Values are presented as the mean ± SD; 
n = 3. Experiments were performed 3 times with similar results. 
*P < 0.05, **P < 0.01 vs control
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Discussion
VSMCs proliferation plays a critical role in the patho-
genesis of various proliferative vascular diseases, such 
as atherosclerosis [23]. The inhibition of VSMC pro-
liferation can be used as an approach to treating prolif-
erative vascular diseases. TNF-α is produced in VSMCs 
and is involved in the production of cytokines, which 
can promote VSMCs proliferation and migration [24, 
25]. Aspirin, a non-steroidal anti-inflammatory drug, has 
multiple pharmacological effects on inhibiting neointimal 
hyperplasia, thrombosis and proliferation. To confirm 
this role of aspirin in VSMCs, a group of cells was treated 
with aspirin for 1 h before being given TNF-α. We found 
that aspirin significantly inhibited the VSMC prolif-
eration induced by TNF-α. We also found that when 
miR-145 expression was down-regulated by the miR-
145 inhibitor, the inhibitory effect of aspirin on VSMCs 
proliferation was blocked. Calponin is a differentiation 
marker gene of VSMC. We used the mRNA expression 
of Calponin to evaluate the proliferation of VSMCs. The 
Fig. 2 miR-145 mediates the anti-proliferative effect of aspirin in TNF-α treated VSMCs. VSMCs in different groups were treated as previously 
described. a The proliferation of VSMCs was determined by EdU; b statistical analyses of VSMCs proliferation; c the level of Calponin expression 
was determined by real-time PCR, and values are presented as the mean ± SD; n = 3. Experiments were performed 3 times with similar results. 
*P < 0.05, **P < 0.01 vs DMSO, ##P < 0.01 vs TNF-α, &&P < 0.01 vs +ASA
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Fig. 3 Evaluation of CD40 protein expression by flow cytometry inVSMCs. a CD40 expression on VSMCs with different treatment. b CD40 expres-
sion was determined by flow cytometry. c Statistical analyses of CD40 expression (%). Values are presented as mean ± SD; n = 3. Experiments were 
performed 3 times with similar results. *P < 0.05 vs DMSO, #P < 0.05 vs TNF-α, &P < 0.05 vs +ASA
Fig. 4 miR-145 mediates the effect of aspirin on CD40 expression induced by TNF-α. The levels of miR-145 expression (a) and CD40 mRNA expres-
sion (b) were determined by real-time PCR. Values are presented as the mean ± SD; n = 3. Experiments were performed 3 times with similar results. 
**P < 0.01 vs DMSO, ##P < 0.01 vs TNF-α, &&P < 0.01 vs +ASA
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results of our study show that the regulatory effect of 
aspirin on Calponin mRNA expression needs miR-145 in 
accordance with the cell proliferation tested by the EdU 
assay. Above all, it is possible that the role of aspirin in 
suppressing cell proliferation is mediated by miR-145.
To further confirm the role of miR-145 in aspirin’s 
pharmacologically mediated effect, miR-145 expres-
sion was determined in VSMCs. The level of miR-145 
expression decreased in the TNF-α group, and aspi-
rin could up-regulate miR-145 expression, which was 
inhibited by TNF-α. Whereas the increase of miR-145 
induced by aspirin disappeared upon intervention with 
the miR-145 inhibitor. This suggested that aspirin has 
an important role in regulating miR-145 expression. 
In agreement with the in  vitro experiments, we also 
observed a definite association between aspirin and the 
expression of miR-145 in IS patients. Moreover, the ath-
erosclerotic plaque from AS patients with aspirin treat-
ment showed increased miR-145 and decreased CD40 
levels compared to those from AS patients without aspi-
rin treatment.
VSMCs can be induced to express CD40 by stimulation 
with TNF-α [26]. CD40L is involved in the process of 
inflammation, which mediates the progression of athero-
sclerotic disease. CD40-CD40L interaction also mediates 
plaque stability. In our study, CD40 mRNA expression 
was up-regulated by TNF-α and down-regulated by aspi-
rin. Furthermore, the role of aspirin on CD40 mRNA 
expression was reversed with the miR-145 inhibi-
tor. A similar trend was also observed in CD40 protein 
Fig. 5 miR-145 mediates the effect of aspirin on CD40 protein expression induced by TNF-α. a The level of CD40 protein was determined by West-
ern blot. b Statistical analyses of CD40 protein. Values are presented as the mean ± SD; n = 3. Experiments were performed 3 times with similar 
results. *P < 0.05 vs DMSO, #P < 0.05 vs TNF-α, &&P < 0.01 vs +ASA
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expression. Furthermore, there was a negative correlation 
between miR-145 and CD40 mRNA expression. These 
data showed that the effect of aspirin on CD40 expres-
sion induced by TNF-α was mediated by miR-145.
Inflammatory mediators, such as TNF-α and IL-6, 
can change VSMC survival and coronary plaque integ-
rity [27]. The expression of IL-6 was elevated in serum 
and atherosclerotic plaques compared with that in 
the control [28, 29]. Previous researchers have dem-
onstrated that IL-6 can induce vascular endothelial 
growth and is involved in regulating cell proliferation 
[30]. High levels of IL-6 have also been proved to be 
associated with cardiovascular diseases and the devel-
opment of coronary disease in people without clinically 
established cardiac vascular diseases [31]. Emerg-
ing evidence has also identified a strong correlation 
between CD40-CD40L and IL-6 [32]. To determine the 
correlation between aspirin and IL-6 in VSMCs, we 
evaluated the levels of IL-6 in culture supernatants. As 
we have shown, aspirin significantly reduced the level 
of IL-6 induced by TNF-α, whereas the role of aspirin 
was mediated by miR-145.
Fig. 6 The effect of aspirin on miR-145 and CD40 expression in VSMCs. The levels of miR-145 expression (a) and CD40 mRNA expression (b) 
were determined by real-time PCR. c The level of CD40 protein was determined by Western blot. Values are presented as the mean ± SD; n = 3. 
**P < 0.01 vs DMSO
Fig. 7 miR-145 mediates the effect of aspirin on IL-6 induced by TNF-
α. Values are presented as the mean ± SD; n = 3. Experiments were 
performed 3 times with similar results. **P<0.01 vs DMSO, ##P < 0.01 
vs TNF-α, &&P < 0.01 vs +ASA
Fig. 8 The influence of aspirin on the expression of miR-145 in IS 
patients. Values are presented as the mean ± SD; n = 46. **P < 0.01 
vs before treatment
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Conclusions
Our data indicate that aspirin significantly decreased 
the level of IL-6 in VSMC supernatants and suppressed 
VSMC proliferation and CD40 mRNA expression, as well 
as CD40 protein expression. When miR-145 expression 
was down-regulated by the miR-145 inhibitor, the effect 
of aspirin on VSMCs was reversed. This result suggested 
that miR-145 mediates the suppression of aspirin of CD40 
induced by TNF-α. However, further research focusing on 
the role of miR-145 in inflammation or CVD/atheroscle-
rosis model is still necessary to verify our findings. In con-
clusion, our study indicates that miR-145 is involved in the 
mechanism of aspirin’s inhibition of VSMC proliferation. 
These findings will help advance our understanding of the 
mechanism of aspirin’s inhibition of VSMC proliferation.
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